Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.
In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.
The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.
Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
TRK inhibitor larotrectinib led to durable responses in people with colon, pancreatic, appendix, bile duct and liver cancers.
Between August 2018 and January 2019, the FDA doubled the number of liver cancer treatments.
With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.
Cabometyx is the third liver cancer drug approved in the past six months.
Lenvima works as well as standard therapy for metastatic or unresectable cancer.
Twice as many patients were alive 18 months after starting treatment.
Recommendations now include multiple systemic medications in addition to surgery and local therapies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.